Compare CIA & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIA | MDWD |
|---|---|---|
| Founded | 1969 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Life Insurance | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.0M | 224.6M |
| IPO Year | 1995 | 2013 |
| Metric | CIA | MDWD |
|---|---|---|
| Price | $4.58 | $15.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | ★ 144.5K | 65.7K |
| Earning Date | 03-12-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $255,616,000.00 | N/A |
| Revenue This Year | $3.10 | $48.88 |
| Revenue Next Year | $4.47 | $35.08 |
| P/E Ratio | $28.23 | ★ N/A |
| Revenue Growth | ★ 4.33 | N/A |
| 52 Week Low | $2.90 | $14.14 |
| 52 Week High | $6.40 | $22.51 |
| Indicator | CIA | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 36.21 | 31.36 |
| Support Level | $4.53 | N/A |
| Resistance Level | $5.44 | $18.58 |
| Average True Range (ATR) | 0.31 | 0.59 |
| MACD | -0.02 | -0.15 |
| Stochastic Oscillator | 18.75 | 10.15 |
Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States. The company provides insurance benefits to residents in thirty two U.S. states and more than seventy countries through its insurance subsidiaries. The company operates in two business segments namely the Life Insurance segment and the Home Service Insurance segment. The company majority generates revenues from Life Insurance segment. Company operates in USA, Columbia, Taiwan, Venezuela, Ecuador, Argentina, and Others.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.